GlassScriptPhysician profile
Rita Deriks
NPI 1720798184
$850.57
in general payments reported to CMS, 2019-2025
21 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $259 · 2024: $308 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $262.06 | 2023-2025 | Endurant Iis, Valiant Captivia, Hawkone |
| Kestra Medical Technology Services, INC. | $96.34 | 2023-2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $43.76 | 2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.71 | 2023-2024 | Jardiance |
| Karl Storz Endoscopy-America | $39.90 | 2023 | |
| Surmodics, INC. | $38.38 | 2023-2025 | Pounce Venous Thrombectomy System, Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Xl Thrombectomy |
| Endologix LLC | $36.81 | 2024 | Torus Stent Graft System, Endocross Device |
| Depuy Synthes Sales INC. | $29.30 | 2025 | |
| Edwards Lifesciences Corporation | $26.85 | 2025 | Evoque |
| Abiomed | $26.83 | 2023 | Impella |
| Astrazeneca Pharmaceuticals LP | $24.15 | 2023 | Andexxa |
| Merck Sharp & Dohme LLC | $23.18 | 2024 | Verquvo |
| Cvrx, INC. | $20.39 | 2025 | Barostim Neo System |
| Solventum Corporation | $20.24 | 2025 | Activ.A.C. |
| Esperion Therapeutics, INC. | $19.29 | 2024 | Nexletol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $18.12 | 2024 | |
| Ethicon US, LLC | $17.44 | 2024 | Stratafix, Ethicon |
| Glaxosmithkline, LLC. | $17.21 | 2025 | Shingrix |
| Alnylam Pharmaceuticals INC. | $17.20 | 2024 | Onpattro |
| Boston Scientific Corporation | $14.88 | 2025 | Enroute Transcarotid Stent |
| Amgen INC. | $14.53 | 2023 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Deriks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.